Upon receipt of marketing authorisation by the European Medicines Agency (EMA), doses of BNT162b2 vaccine are ordered by EU Member States. Pfizer and BioNTech declined to comment on pricing. A spokesman for the European Commission, which negotiates vaccination agreements on behalf of EU member states, also declined to take a position. „Pending the completion of all necessary steps and the authorisation of a vaccine for use by the Medicines Authority, the MHRA, the public must continue to take the necessary measures to protect themselves and their loved ones, including compliance with hands, Face, Space Guidance and other public health boards, in accordance with the area in which they live.“ the government said in a statement yesterday. Finally, based on the measures already approved under the TRIPS Agreement, many disadvantaged countries and groups will still not have access to new treatments and vaccines. The TRIPS Agreement allows countries to grant compulsory licences to their own manufacturers of medicines if they have not been able to negotiate a satisfactory agreement with the innovative company and in cases of extreme urgency (Article 31). The rules also allow countries that do not have production capacity to import these medicines under licence (Article 31bis), although this has only happened once. In these cases, the government chooses a reasonable amount to pay the innovative pharmaceutical company. Australia`s COVID-19 vaccine portfolio now includes two protein vaccines (Novavax, CSL) and an RNA vaccine (Pfizer) and a vaccine against the virus (AZ).